Related Content
- Big Molecule WatchJune 16, 2025
Biosimilar Manufacturers to Expand Offerings in Europe and Japan
- Big Molecule WatchJune 13, 2025
Third Circuit Holds That Granting Discovery Under Section 1782 Is Not a “Final” Judgment
- Big Molecule WatchJune 4, 2025
Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe
- Big Molecule WatchJune 3, 2025
Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva
- Big Molecule WatchJune 2, 2025
EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars
- Big Molecule WatchJune 2, 2025
Celltrion, Samsung Bioepis, and Organon Receive Interchangeability Designations for Adalimumab Biosimilars
- Big Molecule WatchMay 29, 2025
FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar
- Big Molecule WatchMay 23, 2025
FDA Approves BLA for Novavax’s COVID-19 Vaccine
- Awards and RankingsSeptember 9, 2024
Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year